Article info

Original research
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

Authors

  • Francisco J Cueto Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Carlos del Fresno Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, SpainHospital la Paz Institute for Health Research (IdiPAZ), Madrid, Spain PubMed articlesGoogle scholar articles
  • Paola Brandi Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Alexis J. Combes Department of Pathology, University of California, San Francisco, California, USAImmunoX Initiative, University of California, San Francisco, California, USAUCSF CoLabs, University of California, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Elena Hernández-García Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain PubMed articlesGoogle scholar articles
  • Alfonso R Sánchez-Paulete Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Michel Enamorado Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, SpainMetaorganism Immunity Section, Laboratory of Host Immunity and Microbiome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Christian P Bromley Cancer Inflammation and Immunity Group, CRUK Manchester Institute, The University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Manuel J Gomez Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Ruth Conde-Garrosa Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Santos Mañes Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, Madrid, Spain PubMed articlesGoogle scholar articles
  • Santiago Zelenay Cancer Inflammation and Immunity Group, CRUK Manchester Institute, The University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Ignacio Melero Division of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, SpainInstituto de Investigación Sanitaria de Navarra, Pamplona, SpainUniversity Clinic, University of Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Salvador Iborra Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain PubMed articlesGoogle scholar articles
  • Matthew F. Krummel Department of Pathology, University of California, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • David Sancho Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr David Sancho; dsancho{at}cnic.es
View Full Text

Citation

Cueto FJ, del Fresno C, Brandi P, et al
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

Publication history

  • Accepted March 23, 2021
  • First published May 12, 2021.
Online issue publication 
February 07, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.